Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

370
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
370
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

310
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
310
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

335
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
335
Model Approaches for Pharmacokinetic Data: Physiological Models01:15

Model Approaches for Pharmacokinetic Data: Physiological Models

336
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
336
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

449
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
449
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models00:57

Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models

434
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
434

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mechanistic Modelling of Lidocaine and Prilocaine Absorption from EMLA Cream upon Topical Application using Physiologically Based Pharmacokinetic Modelling.

AAPS PharmSciTech·2025
Same author

An α-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer.

Hepatology (Baltimore, Md.)·2025
Same author

The Probiotic Parabacteroides johnsonii Ameliorates Metabolic Disorders Through Promoting BCAAs to BSCFAs Conversion.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Effect of "In Use" Administration on Topical Product Metamorphosis and Skin Permeation of Acyclovir Creams: Implications for Bioequivalence.

Pharmaceutical research·2024
Same author

STING Nanoagonist Boosts Antitumor Immunity of Therapeutic DNA Vaccines.

Nano letters·2024
Same author

Identification and characterization of TM4SF1<sup>+</sup> tumor self-seeded cells.

Cell reports·2024

Related Experiment Video

Updated: Mar 27, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K

Physiologically Based Pharmacokinetic Model for Long-Circulating Inorganic Nanoparticles.

Xiaowen Liang1, Haolu Wang1, Jeffrey E Grice1

  • 1Therapeutics Research Centre, School of Medicine, The University of Queensland, Translational Research Institute , Woolloongabba, QLD 4102, Australia.

Nano Letters
|January 16, 2016
PubMed
Summary

A new model predicts the in vivo behavior of long-circulating inorganic nanoparticles (NPs). This pharmacokinetic model, based on organ and cellular data, shows reliable predictions across different administration routes and species, highlighting phagocytic cell roles in NP biodistribution.

Keywords:
Physiologically-based pharmacokinetic modelbiodistributioninorganic nanoparticleslong-circulating

More Related Videos

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.6K
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.8K

Related Experiment Videos

Last Updated: Mar 27, 2026

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.9K
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
18:57

Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers

Published on: October 17, 2013

47.6K
Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish
13:34

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Published on: April 16, 2019

9.8K

Area of Science:

  • Pharmacokinetics
  • Nanotoxicology
  • Biomedical Engineering

Background:

  • Understanding the in vivo fate of long-circulating inorganic nanoparticles (NPs) is crucial for their safe and effective application.
  • Existing models often lack the resolution to accurately predict NP disposition at organ and cellular levels.

Purpose of the Study:

  • To develop and validate a physiologically based pharmacokinetic (PBPK) model for inorganic NPs.
  • To predict the in vivo biodistribution and fate of long-circulating inorganic NPs across various routes and species.

Main Methods:

  • Development of a PBPK model incorporating direct visualization of NP disposition.
  • Validation of the model using multiple experimental datasets.
  • Analysis of NP uptake and release by phagocytic cells in target organs.

Main Results:

  • The developed PBPK model accurately characterizes and predicts the in vivo fate of inorganic NPs.
  • The model demonstrated robust inter-route and interspecies predictive capabilities.
  • Biodistribution was found to be significantly influenced by phagocytic cell activity.

Conclusions:

  • Physiologically based pharmacokinetic modeling provides a powerful tool for predicting inorganic NP behavior in vivo.
  • Phagocytic cell uptake and release are key determinants of long-circulating inorganic NP biodistribution.
  • This model can aid in the design and safety assessment of nanomaterials.